Ultrasound-Responsive Polypeptide Particles for Transdermal Vaccine Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current transdermal vaccine delivery methods, such as ultrasound permeabilization and microneedle-assisted delivery, are not effective for high-dose vaccine administration and face challenges with patient compliance and efficiency, lacking a breakthrough technology to compete with traditional injection methods.
Innovation Solution
Development of biodegradable ultrasound-responsive polypeptide particles that generate inertial cavitation upon ultrasound exposure, enabling transdermal administration by creating a sonophoresis effect for enhanced vaccine delivery, with the particles acting as both vaccine carriers and adjuvants, and capable of holding a gas bubble in their cup-shaped structure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ultrasound permeabilization is used to create pores in the skin, then vaccine molecules can pass through the skin, but the delivery effectiveness is insufficient
Solution Approach 1:
The patent introduces ultrasound-responsive particles as intermediary agents that mediate between the ultrasound field and the skin barrier. These particles generate inertial cavitation and microstreaming effects that enhance permeabilization, enabling effective transdermal delivery of vaccines while maintaining patient compliance and administrative simplicity
Solution Approach 2:
The patent modifies the physical parameters of the skin barrier through controlled inertial cavitation and microstreaming effects generated by ultrasound-responsive particles. This dynamic parameter change enables temporary opening of skin pathways, allowing vaccine molecules to penetrate effectively without requiring invasive procedures
2Reliability
If microneedles are used to create pores in the skin, then vaccine molecules can pass through, but high-dose vaccine delivery is not suitable and patient compliance is low
Solution Approach 1:
The patent replaces the mechanical microneedle system with an acoustic field-based approach. Ultrasound-responsive particles generate inertial cavitation and microstreaming effects that create pathways for vaccine delivery without requiring physical needles, thereby eliminating pain and needle-stick injuries while maintaining high-dose delivery capability and improving patient compliance
3Productivity
If microbubbles are used as cavitation agents, then drug delivery to target site is enhanced, but the duration of action is very short (no more than 30 seconds)
Solution Approach 1:
The patent employs biodegradable polypeptide particles as replaceable cavitation agents that can be continuously supplied. These particles generate sustained inertial cavitation and microstreaming effects for approximately 10 minutes, providing prolonged action compared to microbubbles. The particles are designed to be consumed during the cavitation process, allowing continuous delivery until the vaccine is administered
Solution Approach 2:
The patent ensures continuous useful action by using particles that maintain cavitation and microstreaming effects throughout the administration process. The polypeptide particles provide sustained mechanical energy transfer to the skin and vaccine molecules, enabling continuous penetration and delivery without the 30-second limitation of microbubbles
4Duration of action of moving object
If plastic particles are used as cavitation agents, then longer duration of action is achieved, but the particles are non-biodegradable and unsuitable for transdermal administration
Solution Approach 1:
The patent changes the material composition parameter from non-biodegradable plastic to biodegradable polypeptide. This material substitution maintains the desired cavitation duration (approximately 10 minutes) while eliminating harmful non-biodegradable components. The polypeptide particles are designed to break down naturally in the body after serving their cavitation function, making them safe for transdermal administration
Solution Approach 2:
The patent uses composite polypeptide particles that combine the cavitation-generating properties needed for prolonged action with biodegradability. The particles consist of polypeptide materials that can undergo controlled degradation, providing both sustained cavitation effects and biological safety, thereby resolving the contradiction between duration and biodegradability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide particles achieve effective transdermal delivery of vaccines, generating a significant immune response and providing a stable, biodegradable solution with prolonged cavitation duration, comparable to traditional injection methods in terms of immune response and compliance.
Implementation Method 1
The particles generate inertial cavitation on response to ultrasound and this property provides the ability to administer both the particles, and any co-administered substances, transdermally
Implementation Method 2
Application of the particles of the invention to the skin, followed by applying ultrasound, generates an inertial cavitation effect sufficient to drive the particles through the skin
Implementation Method 3
The movement of particles across the skin (sonophoresis) is significantly enhanced by the shock wave and/or microstreaming effects generated by the inertial cavitation
Implementation Method 4
The particles described are formed by seed polymerisation to generate cup-shaped plastic particles, capable of holding a gas bubble in the cavity of the cup
Data Source
AI summary
The invention describes transdermal vaccines which contain ultrasound responsive particles comprising a polypeptide shell. The surface of the particle has one or more indentations which are generally able to entrap a gas bubble. The particles are capable of generating inertial cavitation on exposure to ultrasound. The particles can be delivered transdermally, and can comprise antigen protein and/or adjuvant within the particle structure. The particles are therefore useful in methods of vaccination using transdermal delivery routes.